Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jenner

Showing results (11-20 of 548) with videos related to

Pageof 55
Sort By:
Journal of Neurology|January 1, 1992
Parkinson's disease: pathological mechanisms and actions of piribedilP Jenner
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 1989
Clues to the mechanism underlying dopamine cell death in Parkinson's diseaseP Jenner
Neurologic Clinics|May 1, 1992
What process causes nigral cell death in Parkinson's disease?P Jenner
Journal of Neurology|September 19, 2000
Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatmentsP Jenner
Trends in Neurosciences|April 20, 2001
Parkinson's disease, pesticides and mitochondrial dysfunctionP Jenner
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 1, 1971
The role of nitrogen oxidation in the excretion of drugs and foreign compoundsP Jenner
European Journal of Neurology|August 22, 2008
Dopamine agonists in Parkinson's disease--focus on non-motor symptomsP Jenner
Brain Research|December 4, 2001
6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidaseG Kunikowska, P Jenner
American Journal of Clinical Pathology|May 1, 1990
Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Implications for reducing donor exposureM Hoffman, P Jenner
European Journal of Neurology|January 7, 2012
Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's diseaseO Gershanik, P Jenner
Pageof 55

Showing results (11-20 of 548) with videos related to

Sort By:
Pageof 55
Journal of Neurology|January 1, 1992
Parkinson's disease: pathological mechanisms and actions of piribedilP Jenner
Journal of Neurology, Neurosurgery, and Psychiatry|June 1, 1989
Clues to the mechanism underlying dopamine cell death in Parkinson's diseaseP Jenner
Neurologic Clinics|May 1, 1992
What process causes nigral cell death in Parkinson's disease?P Jenner
Journal of Neurology|September 19, 2000
Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatmentsP Jenner
Trends in Neurosciences|April 20, 2001
Parkinson's disease, pesticides and mitochondrial dysfunctionP Jenner
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 1, 1971
The role of nitrogen oxidation in the excretion of drugs and foreign compoundsP Jenner
European Journal of Neurology|August 22, 2008
Dopamine agonists in Parkinson's disease--focus on non-motor symptomsP Jenner
Brain Research|December 4, 2001
6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidaseG Kunikowska, P Jenner
American Journal of Clinical Pathology|May 1, 1990
Variability in the fibrinogen and von Willebrand factor content of cryoprecipitate. Implications for reducing donor exposureM Hoffman, P Jenner
European Journal of Neurology|January 7, 2012
Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's diseaseO Gershanik, P Jenner
Pageof 55